Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05717400 · ClinicalTrials.gov registry record · Phase 4
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
A Phase 4 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT05717400: Clinical Trial Phase 4 study, sponsored by M.D. Anderson Cancer Center.
NCT05717400 is a Phase 4 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05717400, a Phase 4 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
To learn if giving immune checkpoint therapy (such as atezolizumab) and bevacizumab to patients who have HCC and are receiving DAAs may help to control HCC and hepatitis C.
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Sofosbuvir
- DRUG Velpatasvir
- DRUG Voxilaprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-03-17 |
| Est. Completion | 2024-08-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05717400
The ClinicalTrials.gov registry entry for NCT05717400 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT05717400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05717400 about?
NCT05717400 is a clinical study titled "Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy". To learn if giving immune checkpoint therapy (such as atezolizumab) and bevacizumab to patients who have HCC and are receiving DAAs may help to control HCC and hepatitis C.
What is the current status of trial NCT05717400?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2023-03-17. Estimated completion is 2024-08-29.
What interventions are being tested in trial NCT05717400?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Sofosbuvir (DRUG), Velpatasvir (DRUG), Voxilaprevir (DRUG).
Who is sponsoring clinical trial NCT05717400?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.